Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.
Moore
Mary Courtney
MC
Vanderbilt University School of Medicine, Department of Molecular Physiology and Biophysics, 702 Light Hall, Nashville, TN 37232, USA. genie.moore@vanderbilt.edu
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006601:Hexoses / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D009765:Obesity / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D019440:Anti-Obesity Agents; D006601:Hexoses; D007004:Hypoglycemic Agents; C030192:tagatose